More than a decade after tightening exposure standards for dioxin, federal regulators have yet to reassess the potential health risks posed by the hazardous industrial byproduct to Jacksonville residents living near what was once among the worst Superfund sites in the nation.
(1)
LAS VEGAS, NV / ACCESSWIRE / January 25, 2021 / GB Sciences, Inc. (OTCQB:GBLX), through GBS Global Biopharma, Inc. ( GBS ), has executed a Sponsored Research Agreement with Michigan State University (MSU) to obtain valuable proof-of-concept data to support the use of their new proprietary cannabinoid containing complex mixtures (CCCM) for the treatment of Cytokine Release Syndrome (CRS) and associated hyperinflammatory conditions such as macrophage activation syndrome (MAS) and acute respiratory distress syndrome (ARDS) in COVID-19 patients. CRS, MAS, and ARDS are the leading causes of deaths in COVID-19 patients. GBS CCCM were designed to reduce the life-threatening levels of specific cytokines and pro-inflammatory processes triggered by SARS-CoV-2 infections, while preserving those immune functions and cytokines that are necessary for fighting the viral infection.